Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity titled "Expanding the Target Landscape by Drugging the Undruggable," aimed at supporting exploratory projects that target currently undruggable protein classes associated with intractable human diseases. Applicants are required to identify a relevant undruggable target class and propose innovative preclinical methods or agents to address treatment gaps, with a focus on developing strategies that cannot be tackled by existing therapeutic approaches. This initiative is crucial for advancing translational science and improving public health outcomes by fostering the development of novel treatments for conditions that currently lack effective therapies. Up to $275,000 is available for projects over a two-year period, with applications due by February 17, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.